ASTON SCI
Aston Sci is a clinical-stage biopharmaceutical company that develops medicines in oncology, immunology, and geriatrics.
ASTON SCI
Social Links:
Industry:
Biotechnology Oncology Pharmaceutical Product Research
Founded:
2018-01-01
Address:
Seoul, Seoul-t'ukpyolsi, South Korea
Country:
South Korea
Website Url:
http://www.astonsci.com
Total Employee:
11+
Status:
Active
Contact:
+82 02 2038 2347
Total Funding:
27 B KRW
Technology used in webpage:
IPhone / Mobile Compatible Mobile Non Scaleable Content
Similar Organizations
Aclaris Therapeutics
Aclaris Therapeutics is a specialty pharmaceutical company engaged in developing dermatologic therapies.
Adlai Nortye
Adlai Nortye is a clinical-stage biopharmaceutical company that deveops cancer treatments for diverse tumor types.
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
CStone Pharmaceuticals
CStone Pharmaceuticals is a bio-pharmaceutical company develops new treatments in a range of therapeutic areas.
Iroko Pharmaceuticals
Iroko Pharmaceuticals is a global specialty pharmaceutical company dedicated to advancing the science of analgesia.
Jing Medicine Technology
Jing Medicine Technology is a developing innovative therapeutics for Oncology, Immunology and CNS disorders.
Leap Therapeutics
Leap Therapeutics is a clinical-stage biopharmaceutical company.
Navrogen
Navrogen is a biopharmaceutical company focused on the targeted treatment of cancer.
NephroDI Therapeutics
NephroDI Therapeutics is a biopharmaceutical company that focuses on the concentration disorders of the kidney.
TaiRx
TaiRx is an efficient Pharma Management Corporate to develop a new generation of oncology molecule.
Current Employees Featured
Founder
Investors List
Lakewood Partners
Lakewood Partners investment in Series C - Aston Sci
Mirae Asset Venture Investment
Mirae Asset Venture Investment investment in Series C - Aston Sci
Timepolio Asset Management
Timepolio Asset Management investment in Series C - Aston Sci
Gen-tech Investments
Gen-tech Investments investment in Series C - Aston Sci
Mirae Asset
Mirae Asset investment in Series C - Aston Sci
Official Site Inspections
http://www.astonsci.com
- Host name: 211.47.74.16
- IP address: 211.47.74.16
- Location: South Korea
- Latitude: 37.5112
- Longitude: 126.9741
- Timezone: Asia/Seoul
More informations about "Aston Sci"
Aston Sci.
ORGANIZATION. This is our corporate structure. We value people over everything else. corporate registration number. 354 - 88 - 01258 T. 02-2038-2347 ADDRESS. Aston Sci. Inc. Headquarters: A916-917, C-dong, 520, Misa …See details»
ASTON SCI
September 12, 2023 US FDA Approves Aston Sci.’s Phase 2 IND for Ovarian Cancer Vaccine, AST-201 - A New Vaccine Approach for Ovarian Cancer PatientsSeoul, South Korea, Sept. 12, 2023 – Aston Sci. is proud to announce …See details»
Aston Sci.
Corporate registration number. 354 - 88 - 01258 T. 02-2038-2347 ADDRESS. Aston Sci. Inc. Headquarters: 10F, 40, Seolleung-ro 90-gil, Gangnam-gu, Seoul, Republic of Korea 06193 Aston Sci. Inc. R&D Facility: A916-917, C-dong, 520, …See details»
Aston Sci. - LinkedIn
Aston Sci. is a clinical-stage biopharmaceutical company that is currently focusing on the development of innovative medicines in oncology, immunology, and geriatrics, including therapeutic cancer ...See details»
Aston Sci. 2025 Company Profile: Valuation, Funding
Aston Sci. General Information Description. Operator of a biopharmaceutical company intended to develop therapeutic cancer vaccines and proteostasis …See details»
Aston Sci - Crunchbase Company Profile & Funding
Aston Sci is a clinical-stage biopharmaceutical company that develops medicines in oncology, immunology, and geriatrics.See details»
Aston Sci - Products, Competitors, Financials, Employees, …
Aston Sci. Frequently Asked Questions (FAQ). When was Aston Sci founded? Aston Sci was founded in 2018. Where is Aston Sci's headquarters? Aston Sci's headquarters is located at …See details»
Aston Science - Overview, News & Similar companies - ZoomInfo
Sep 11, 2023 Aston Science contact info: Phone number: +82 220382347 Website: www.astonsci.com What does Aston Science do? Aston Science is a clinical-stage …See details»
Aston Sci. - VentureRadar
Website: http://astonsci.com/ Develops innovative medicines in oncology, immunology, and geriatrics, specializing in therapeutic cancer vaccines to combat recurrence ...See details»
Nextsource | Company Profile | Aston Sci
Explore the company profile of Aston Sci (astonsci.com) featuring business details and insights, funding data, industry info, employee numbers, and more.See details»
Aston SCI - Drug pipelines, Patents, Clinical trials
Mar 8, 2025 Explore Aston SCI with its drug pipeline, therapeutic area, technology platform, 4 clinical trials, 4 news, and 1 literature, Disease Domain:Neoplasms, Endocrinology and Metabolic Disease, Hemic and …See details»
Paclitaxel and Carboplatin and rhuGM-CSF(Granulocyte ... - ICH GCP
Mar 7, 2023 Study Director: Hyunwon Shin, MD, PhD, [email protected] Study record dates These dates track the progress of study record and summary results submissions …See details»
AST-201 - Drug Targets, Indications, Patents - Synapse
Mar 20, 2025 Inactive Organization-Drug Highest Phase Phase 2. First Approval Date-Regulation-Login to view timeline. Related. 1. ... · astonsci.com. US FDA Approves Aston …See details»
Science - ASTON SCI
Corporate registration number. 354 - 88 - 01258 T. 02-2038-2347 ADDRESS. Aston Sci. Inc. Headquarters: A916-917, C-dong, 520, Misa-daero, Hanam-si, Gyeonggi-do, Republic of …See details»
US FDA Approves Aston Sci.'s Phase 2 IND for Ovarian Cancer …
Sep 12, 2023 A New Vaccine Approach for Ovarian Cancer Patients. SEOUL, South Korea, Sept. 12, 2023 /PRNewswire/ -- Aston Sci. is proud to announce that it has received Phase 2 …See details»
Novel HER2-hICD Vaccine to be Investigated for Treatment of …
Sep 2, 2022 Recruitement contact:Eunkyo Joung, CMO02-2038-2347 [email protected] or [email protected] "It is a remarkable milestone that is …See details»
US FDA Approves Aston Sci.'s Phase 2 IND for Ovarian Cancer …
Sep 12, 2023 A New Vaccine Approach for Ovarian Cancer Patients. SEOUL, South Korea, Sept. 12, 2023 /PRNewswire/ -- Aston Sci. is proud to announce that it has received Phase 2 …See details»
HISTORY - ASTON SCI
Organization; History; HISTORY. We are building our own path to success. 20. 20 18. Oct. Founded Aston Sci. Inc. 20 19. Mar. Initiated preparation of AST-301 (therapeutic cancer …See details»
PRESS RELEASE - ASTON SCI
2023-09-12 US FDA Approves Aston Sci.’s Phase 2 IND for Ovarian Cancer Vaccine, AST-201 - A New Vaccine Approach for Ovarian Cancer PatientsSeoul, South Korea, Sept. 12, 2023 – …See details»
Aston Sci.
Overview • Dosing formulation: pDNA-based vaccine • Proximal target as a mode of action: elicits the CD4+ Th1-specific immunity against HER2, IGFBP-2, and IGF-1RSee details»